103 related articles for article (PubMed ID: 21516127)
1. Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer.
Reimer D; Hubalek M; Kiefel H; Riedle S; Skvortsov S; Erdel M; Hofstetter G; Concin N; Fiegl H; Müller-Holzner E; Marth C; Altevogt P; Zeimet AG
Oncogene; 2011 Sep; 30(38):4038-49. PubMed ID: 21516127
[TBL] [Abstract][Full Text] [Related]
2. E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer.
Reimer D; Hubalek M; Riedle S; Skvortsov S; Erdel M; Concin N; Fiegl H; Müller-Holzner E; Marth C; Illmensee K; Altevogt P; Zeimet AG
Cancer Res; 2010 Jun; 70(11):4613-23. PubMed ID: 20460525
[TBL] [Abstract][Full Text] [Related]
3. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG
BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Tropé CG; Nesland JM; Holm R
Anticancer Res; 1999; 19(5C):4469-74. PubMed ID: 10650794
[TBL] [Abstract][Full Text] [Related]
5. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
Gallardo E; Navarro A; Viñolas N; Marrades RM; Diaz T; Gel B; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307
[TBL] [Abstract][Full Text] [Related]
6. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer.
Oeggerli M; Schraml P; Ruiz C; Bloch M; Novotny H; Mirlacher M; Sauter G; Simon R
Oncogene; 2006 Oct; 25(49):6538-43. PubMed ID: 16953223
[TBL] [Abstract][Full Text] [Related]
7. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
8. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
[TBL] [Abstract][Full Text] [Related]
9. Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer.
Ilekis JV; Gariti J; Niederberger C; Scoccia B
Gynecol Oncol; 1997 Apr; 65(1):36-41. PubMed ID: 9103388
[TBL] [Abstract][Full Text] [Related]
10. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Hata K; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Miyazaki K
Gynecol Oncol; 2004 Apr; 93(1):215-22. PubMed ID: 15047239
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
Reimer D; Sadr S; Wiedemair A; Stadlmann S; Concin N; Hofstetter G; Müller-Holzner E; Marth C; Zeimet AG
Clin Cancer Res; 2007 Jan; 13(1):144-51. PubMed ID: 17200349
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
14. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer.
Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Puopolo M; Schwartz P; Yu H
Gynecol Oncol; 2006 Dec; 103(3):990-5. PubMed ID: 16859738
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.
Schlomm T; Kirstein P; Iwers L; Daniel B; Steuber T; Walz J; Chun FH; Haese A; Kollermann J; Graefen M; Huland H; Sauter G; Simon R; Erbersdobler A
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6579-84. PubMed ID: 18006757
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
[TBL] [Abstract][Full Text] [Related]
17. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
18. Decreased survival in EGFR gene amplified vulvar carcinoma.
Growdon WB; Boisvert SL; Akhavanfard S; Oliva E; Dias-Santagata DC; Kojiro S; Horowitz NS; Iafrate AJ; Borger DR; Rueda BR
Gynecol Oncol; 2008 Nov; 111(2):289-97. PubMed ID: 18768215
[TBL] [Abstract][Full Text] [Related]
19. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer.
Psyrri A; Kassar M; Yu Z; Bamias A; Weinberger PM; Markakis S; Kowalski D; Camp RL; Rimm DL; Dimopoulos MA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8637-43. PubMed ID: 16361548
[TBL] [Abstract][Full Text] [Related]
20. Transgenic expression of E2F3a causes DNA damage leading to ATM-dependent apoptosis.
Paulson QX; Pusapati RV; Hong S; Weaks RL; Conti CJ; Johnson DG
Oncogene; 2008 Aug; 27(36):4954-61. PubMed ID: 18469863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
